Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | BRD2 | P25440 | 1/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28574414 | 0.98 | ALDH1A1 (0.97) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1BRD4 | |
| SCHEMBL26064876 | 0.87 | ALDH1A1 (0.77) | ALDH1A1SMN1; SMN2USP2KMT2AGAA | |
| SCHEMBL2081742 | 0.84 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2L3MBTL1BRD4BRD2 | |
| SCHEMBL15872007 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1TDP1 | |
| SCHEMBL4555634 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1TDP1 | |
| SCHEMBL9267796 | 0.83 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1BRD4 | |
| SCHEMBL14538102 | 0.82 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2RAB9AKMT2AGAA | |
| SCHEMBL7257868 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1BRD4 | |
| SCHEMBL309043 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2L3MBTL1BRD4BRD2 | |
| SCHEMBL10042198 | 0.81 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2RAB9AL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536183-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2013-09-17 | — | — | US | disclosed |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | BESWICK PAUL JOHN (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8288388-B2 | 3-pyridylcarbonyl-piperazinylsulfonyl derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-10-16 | — | — | US | disclosed |
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100022555-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | ALDH1A1 3984/4885SMN1; SMN2 809/4885RAB9A 2604/4885 |
| US-20100022555-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | ALDH1A1 3984/4885SMN1; SMN2 809/4885RAB9A 2604/4885 |
| US-20120302746-A1 | 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES | CACNB2, CACNA1C, KCNJ2 | ALDH1A1 3994/4885SMN1; SMN2 463/4885RAB9A 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.